Veracyte Inc
NASDAQ:VCYT
Relative Value
The Relative Value of one VCYT stock under the Base Case scenario is 26.56 USD. Compared to the current market price of 20.13 USD, Veracyte Inc is Undervalued by 24%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
VCYT Competitors Multiples
Veracyte Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Veracyte Inc
NASDAQ:VCYT
|
1.5B USD | 4.1 | -19.8 | 129.2 | -72.1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
148.5B USD | 5.3 | 22.1 | 16.4 | 24.6 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.8B USD | 7.5 | 25 | 16.6 | 18.2 | ||
AU |
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.6 | 6.8 | 8.9 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.5 | -8.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | ||
KR |
Celltrion Inc
KRX:068270
|
39.3T KRW | 18.1 | 73.4 | 44.9 | 61.8 |